Long-Term Safety and Efficacy of Mitapivat (AG-348), a Pyruvate Kinase Activator, in Patients with Pyruvate Kinase Deficiency: The DRIVE PK Study
Rachael F. Grace(Dana-Farber/Boston Children's Cancer and Blood Disorders Center), Bertil Glader(Stanford University), Wilma Barcellini(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Chris Mix, Sujit Sheth(Columbia University Irving Medical Center), Yaddanapudi Ravindranath(The Barbara Ann Karmanos Cancer Institute), Kevin H.M. Kuo(University Health Network), Frederic Galactéros(Inserm), Peter Hawkins(Agios Pharmaceuticals (United States)), Janet L. Kwiatkowski(Children's Hospital of Philadelphia), Lei Hua(Agios Pharmaceuticals (United States)), Eduard J. van Beers(Utrecht University), D. Mark Layton(Imperial College Healthcare NHS Trust), Hassan M. Yaish(Primary Children's Hospital)
Cited by 3
Related Papers
Ribosomal Protein L5 and L11 Mutations Are Associated with Cleft Palate and Abnormal Thumbs in Diamond-Blackfan Anemia Patients
|The American Journal of Human Genetics|2008|417
Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients
|Blood|2014|373
Home Treatment of Mild to Moderate Bleeding Episodes Using Recombinant Factor VIIa (Novoseven) in Haemophiliacs with Inhibitors
|Thrombosis and Haemostasis|1998|355